Suchergebnisse

Yes ; The use of Artificial Intelligence (AI) in Digital technologies (DT) is proliferating a profound socio-technical transformation. Governments and AI scholarship have endorsed key AI principles but lack direction at the implementation level. Through a systematic literature review of 59 papers, this paper contributes to the critical debate on the ethical use of AI in DTs beyond high-level AI principles. To our knowledge, this is the first paper that identifies 14 digital ethics implications for the use of AI in seven DT archetypes using a novel ontological framework (physical, cognitive, information, and governance). The paper presents key findings of the review and a conceptual model with twelve propositions highlighting the impact of digital ethics implications on societal impact, as moderated by DT archetypes and mediated by organisational impact. The implications of intelligibility, accountability, fairness, and autonomy (under the cognitive domain), and privacy (under the information domain) are the most widely discussed in our sample. Furthermore, ethical implications related to the governance domain are shown to be generally applicable for most DT archetypes. Implications under the physical domain are less prominent when it comes to AI diffusion with one exception (safety). The key findings and resulting conceptual model have academic and professional implications. ; The full-text of this article will become publicly available at the end of the publisher embargo on 5 Oct 2023.

For a decade, The Cancer Genome Atlas (TCGA) program collected clinicopathologic annotation data along with multi-platform molecular profiles of more than 11,000 human tumors across 33 different cancer types. TCGA clinical data contain key features representing the democratized nature of the data collection process. To ensure proper use of this large clinical dataset associated with genomic features, we developed a standardized dataset named the TCGA Pan-Cancer Clinical Data Resource (TCGA-CDR), which includes four major clinical outcome endpoints. In addition to detailing major challenges and statistical limitations encountered during the effort of integrating the acquired clinical data, we present a summary that includes endpoint usage recommendations for each cancer type. These TCGA-CDR findings appear to be consistent with cancer genomics studies independent of the TCGA effort and provide opportunities for investigating cancer biology using clinical correlates at an unprecedented scale. Analysis of clinicopathologic annotations for over 11,000 cancer patients in the TCGA program leads to the generation of TCGA Clinical Data Resource, which provides recommendations of clinical outcome endpoint usage for 33 cancer types.